Evidence map›Paper›PMID 42222481›Full record

ArticlePeerJ2026

An autoantibody signature targeting cuproptosis-related proteins for non-small cell lung cancer detection and prognosis.

Aichen Liu, Lulu Zhang, Peiqi Yu, Tingzun Nie, Xiaobin Cao, Jing Li, Wenke Sun, Yihao Liang, Songyun Ouyang, Liping Dai and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Aichen LiuHenan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou City, Henan Province, China.
Lulu ZhangHenan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou City, Henan Province, China.
Peiqi YuHenan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou City, Henan Province, China.
Tingzun NieHenan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou City, Henan Province, China.
Xiaobin CaoHenan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou City, Henan Province, China.
Jing LiHenan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou City, Henan Province, China.
Wenke SunHenan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou City, Henan Province, China.
Yihao LiangHenan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou City, Henan Province, China.
Songyun OuyangFirst Affiliated Hospital of Zhengzhou University, Zhengzhou City, Henan Province, China.
Liping DaiHenan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou City, Henan Province, China.
Jingjing LiuHenan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou City, Henan Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Autoantibodies against tumor-associated antigens in plasma are valuable biomarkers for early cancer detection and prognostic stratification. Dihydrolipoamide acetyltransferase (DLAT) and lipoic acid synthetase (LIAS), two key cuproptosis regulators, are abnormally expressed in non-small cell lung cancer (NSCLC) and are potential biomarkers for clinical diagnosis. This study explored the significance of anti-DLAT and anti-LIAS autoantibodies in the clinical diagnosis and prognosis of NSCLC. Methods: Plasma levels of anti-DLAT and anti-LIAS autoantibodies were detected using Enzyme-Linked Immunosorbent Assay (ELISA). Their diagnostic value was evaluated in 340 cases with normal control (NC), 260 patients with benign pulmonary nodule (BPN) and 340 patients with NSCLC. Additionally, the prognostic value of these autoantibodies was analyzed in a separate independent cohort of 354 patients with NSCLC. Results: The expression levels of anti-DLAT and anti-LIAS autoantibodies were significantly elevated in NSCLC compared to those in BPN and NC. These autoantibodies distinguished NSCLC from NC with AUCs of 0.712 (95% CI [0.669-0.756]) and 0.668 (95% CI [0.623-0.714]), respectively. To enhance diagnostic efficacy, a multi-autoantibody signature (anti-DLAT/LIAS/FDX1/COPT1) was constructed, which significantly improved discrimination (NSCLC Conclusions: These findings demonstrate the clinical utility of an autoantibody signature targeting cuproptosis-related proteins for NSCLC diagnosis and prognosis.

Indexed as

AutoantibodiesBiomarkers, TumorCarcinoma, Non-Small-Cell LungCuproptosisLung NeoplasmsAdultAgedEnzyme-Linked Immunosorbent AssayFemaleHumansMaleMiddle AgedPrognosisAutoantibodiesBiomarkers, TumorAutoantibodyCuproptosis-related proteinsDetection and prognosisNon-small cell lung cancer

Identifiers

PMID42222481
PMCPMC13221990

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.